Clinton F. Stewart, PharmD
Clinton F. Stewart, PharmD

Clinton F. Stewart, PharmD

Member, St. Jude Faculty



BSPh – Auburn University
PharmD – University of Tennessee, Memphis, TN

Honors & Awards

  • 2012 Research Advisor Award, University of Tennessee Health Science Center, College of Graduate Health Sciences
  • 2009 Fellow, American Association of Pharmaceutical Scientists
  • 1994 Fellow, American College of Clinical Pharmacists

Research Interests

  • CNS and tumor penetration of novel agents used to treat pediatric CNS tumors in relevant mouse models
  • Pharmacokinetic and pharmacodynamic modeling and simulation to derive safe and effective anti-cancer drug regimens for infants and young children with brain tumors
  • Novel methods to optimize drug exposure in children with cancer (eg, pharmacokinetically guided dosing)

Improving Drug Therapy for Children with Brain Tumors

Selected Publications

Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R. A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children with Recurrent or Refractory Central Nervous System Malignancies: a Pediatric Brain Tumor Consortium Study. J Neurooncol 129:443-51, 2016. (PMCID: pending)

Wetmore C, Daryani VM, Billups CA, Boyett JM, Leary S, Tanos R, Goldsmith KC, Stewart CF, Blaney SM, Gajjar A. Phase II Evaluation of Sunitinib in the Treatment of Recurrent or Refractory High-Grade Glioma or Ependymoma in Children: a Children’s Oncology Group Study ANS1021. Cancer Med 5:1416-24, 2016. (PMCID: PMC4944867)

Daryani VM, Patel YT, Tagen M, Turner DC, Carcaboso AM, Atkinson JM, Gajar A, Gilbertson RJ, Wright KD, Stewart CF. Translational pharmacokinetic-pharmacodynamic modeling and simulation: optimizing 5-fluorouracil dosing in children with pediatric ependymoma. CPT Pharmacometrics Syst Pharmacol 5:211-221, 2016. (PMCID: PMC4834132)

Roberts JK, Birg AV, Lin T, Daryani VM, Panetta JC, Broniscer A, Robinson GW, Gajjar AJ, Stewart CF. Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. Drug Metab Dispos 44:1116-22, 2016. (PMCID: PMC4931885)

Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, Roussel MF, Finkelstein D, Goumnerova L, Perreault S, Wadhwa E, Cho YJ, Stewart CF, Gilbertson RJ. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell 29: 508-22, 2016.  (PMCID: PMC4829447)

Patel YT, Jacus MO, Davis AD, Boulos N, Turner DC, Vuppala PK, Freeman BB, 3rd, Gilbertson RJ, Stewart CF. Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study. Drug Metab Dispos 44:591-4, 2016.  (PMCID: PMC4810761)

Edelmann MN, Daryani VM, Bishop MW, Liu W, Brinkman TM, Stewart CF, Mulrooney DA,Kimberg C, Ness KK, Cheung YT, Srivastava DK, Robison LL, Hudson MM, Krull KR. Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma. JAMA Oncol 2:201-8, 2016. (PMCID: PMC4752424)

Wright KD, Daryani VM, Turner DC, Onar-Thomas A, Boulos N, Orr BA, Gilbertson RJ, Stewart CF, Gajjar A. Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro Oncol 17:1620-7, 2015. (PMCID: PMC4633933)

Morfouace M, Nimmervoll B, Boulos N, Patel YT, Shelat A, Freeman BB, 3rd, Robinson GW, Wright K, Gajjar A, Stewart CF, Gilbertson RJ, Roussel MF. Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors. J Neurooncol 126:225-34, 2016. (PMCID: PMC4718940)

Jacus MO, Daryani VM, Harstead KE, Patel YT, Throm SL, and Stewart CF. Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. Clin Pharmacokinet 55:297-311, 2016. (PMCID: PMC4761278)

Guo J, Glass JO, McCarville MB, Shulkin BL, Daryani VM, Stewart CF, Wu J, Mao S, Dwek JR, Fayad LM, Madewell JE, Navid F, Daw NC, Reddick WE. Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. Br J Cancer 113:1282-8, 2015. (PMCID: PMC4815789)

Hoffman LM, Fouladi M, Olson J, Daryani VM, Stewart CF, Wetmore C, Kocak M, Onar-Thomas A, Wagner L, Gururangan S, Packer RJ, Blaney SM, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst 31:1283-1289, 2015. (PMCID: PMC4681692)

Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer R, Goldman S, Prados M, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart CF, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A. Vismodegib exerts targeted efficacy against recurrent SHH-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies – PBTC-025B and PBTC-032. J Clin Oncol 33:2646-2654, 2015. (PMCID: PMC4534527)

Morfouace M, Cheepala SB, Jackson S, Fukuda Y, Patel YT, Soghra F, Kawauchi D, Shelat AA, Stewart CF, Sorrentino B, Schuetz JD, Roussel MF. ABCG2 transporter expression impacts Group3 medulloblastoma response to chemotherapy. Cancer Res 75: 3879-3889, 2015. (PMCID: PMC4573843)

Jacus MO, Rahija R, Davis A, Throm SL, Stewart CF. Observational evaluation of mice during cerebral microdialysis procedures used in pediatric brain tumor research. J Am Assoc Lab Anim Sci 54: 304-10, 2015.  (PMCID: PMC4460944)

Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemotherap Pharmacol 75:495-503, 2015. (PMCID: PMC4344382)

Xu H, Robinson GW, Huang Jie, Lim JY-S, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JY. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature Genetics 47:263-266, 2015. (PMCID: PMC4358157)

Patel Y, Jacus M, Boulos N, Dapper J, David A, Vuppala P, Freeman III B, Mohankumar K, Throm S, Gilbertson R, Stewart CF. Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study. Cancer Chemotherap Pharmacol 75:897-906, 2015.  (PMID: PMC4420645)

Wright KD, Panetta JC, Onar-Thomas A, Reddick WE, Patay Z, Qaddoumi I, Broniscer A, Robinson G, Boop FA, Klimo P, Ward D, Gajjar A, Stewart CF. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemother Pharmacol 75:27-35, 2015. (PMCID: PMC4282603)

Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A. Mdm2 and Aurora A inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res 75:181-93, 2015. (PMCID: PMC4286469)

Roberts MS, Turner DC, Broniscer A, Stewart CF. Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). J Chromatography B 960C:151-157, 2014. (PMCID: PMC4062842)

Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, Neel M, Rao B, Willert JR, Loeb DM, Harstead KE, Throm SL, Freeman BB III, Stewart CF. Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res 20:1-10, 2014. (PMCID: PMC4024352)

Morfouace M, Shelat A, Jacus M, Freeman BB 3rd, Robinson S, Turner D, Zindy F, Wang Y-D, Finkelstein D, Bihannic L, Puget S, Ayrault O, Li X-N, Olson JM, Robinson GW, Guy RK, Stewart CF, Gajjar A, Roussel MF. Pemetrexed and gemcitabine as combination therapy for the treatment of group 3 medulloblastoma. Cancer Cell 25(4):516-529, 2014. (PMCID: 24684846).

Jacus MO, Throm SL, Turner DC, Patel YT, Freeman BB 3rd, Morfouace M, Boulos N, Stewart CF. Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data. Eur J Pharm Sci 57:41-7, 2014. (PMCID: 24269626).

Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N, Boyett JM, Gilbertson RJ, Curran T. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res 19:6305-12, 2013. (PMCID:PMC3856244).

Yang JJ, Lim JY-S, Huang J, Bass J, Wu J, Wang C, Fang J, Stewart E, Harstead EH, Shuyu E, Robinson GW, Evans WE, Pappo A, Zuo J, Relling MV, Onar-Thomas A, Gajjar A, Stewart CF. The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin-Induced Ototoxicity in Children with Cancer. Clinical Pharmacol Therap 94:252-9, 2013. (PMCID: PMC3883563)

Broniscer A, Baker SD, Wetmore C, Pai Panadiker A, Huang J, Davidoff AM, Onar-Thomas A, Panetta JC, Chin TK, Merchant TE, Baker JN, Kaste SC, Gajjar A, Stewart CF. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res 19:3050-3058, 2013. (PMCID:PMC3685168)

Roberts MS, Turner DC, Owens TS, Ramachandran A, Wetmore C, Throm SL, Stewart CF. Determination of crenolanib in human serum and cerebrospinal fluid by liquid-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). J Chrom B 292:1-5, 2013. (PMCID: PMC3665945).

Blaney SM, Tagen M, Onar-Thomas A, Berg SL, Gururangan S, Scorsone K, Su J, Goldman S, Kieran MW, Kun L, Boyett J, Stewart C. A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: A pediatric brain tumor consortium study. Pediatr Blood Cancer 60:627-632, 2013. (PMCID: PMC3573253).

Show More

Bai F, Johnson J, Wang F, Yang L, Broniscer A, Stewart CF. Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879:2561-6, 2011. (PMCID: PMC3162072)

Elmeliegy MA, Carcaboso AM, L Chow LM, Zhang ZM, Calabrese C, Throm SL, Wang F, Baker SJ, Stewart CF. Magnetic resonance imaging-guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model. J Pharm Sci 100:4210-4214; 2011. (PMCID:PMC3750095)

Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20:384-99, 2011. (PMCID: PMC3172881)

Zhang F, Throm SL, Murley LL, Miller LA, Zatechka DS, Guy RK, Kennedy R, Stewart CF. MDM2 Antagonist Nutlin-3a Reverses Mitoxantrone Resistance by Inhibiting Breast Cancer Resistance Protein Mediated Drug Transport. Biochem Pharmacol 82:24-24, 2011. (PMCID: PMC3108438)

Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 17:89-99, 2011. (PMCID: PMC3017236)

Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, Dyer MA, Williams RT, Roussel MF, Nemeth K, Zhu F, Zhang J, Lu M, Panetta JC, Boulos N, Stewart CF. Whole-body physiologically-based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Disp 39:15-21, 2011. (PMCID: PMC3014266)

Last update: November 2016